drugset / Trial / NCT00130871

Levosimendan Pretreatment for Weaning Patients From Cardio-Pulmonary Bypass

NCT00130871

Phase 2 Completed 60 enrolled Orion Corporation, Orion Pharma
RandomizedParallel-groupDouble-blindTreatment

Summary

The study evaluates the efficacy of intravenous levosimendan treatment started during a coronary artery bypass operation to wean patients from a heart lung machine.

Timeline

Start
2004-01
Primary completion
Completion
2006-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Levosimendan Other / unclassified Intravenous